Praxis Precision Medicines Inc

Praxis Precision Medicines insider sales show routine tax‑related moves, not distress, while the company eyes FDA approvals that could boost its value.

Praxis Precision Medicines insider sales show a brief liquidity move, not a confidence drop; the firm’s $575 m raise and strong cash reserve keep investor sentiment high and the stock climbing.